Sponsor hub
Alexion Pharmaceuticals, Inc. clinical trial failures
Review 41 stopped clinical trials from Alexion Pharmaceuticals, Inc., including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 22
- OTHER/UNKNOWN
- 13
- EFFICACY/FUTILITY
- 3
- SAFETY
- 3
Notable sponsors
- Alexion Pharmaceuticals, Inc.
- 41
Related phases
- Phase II
- 24
- Phase I
- 9
- Phase III
- 6
- Phase IV
- 2
Crawlable stopped-trial records
Open ExploreShowing up to 41 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II Myocardial Infarction trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Administrative reasons.
Phase II Lupus Nephritis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase IV Hypophosphatasia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision following FDA release from the PMR.
Phase II Ulcerative Colitis, Active Moderate trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase II Lupus Nephritis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor Decision.
Phase II Geographic Atrophy trial by Alexion Pharmaceuticals, Inc.. Stop reason: EFFICACY/FUTILITY.
Lack of efficacy.
Phase II Dermatomyositis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision
Phase I Impaired Hepatic Function trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision.
Phase II Sickle Cell Disease (SCD) trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate program.
Phase II Generalized Myasthenia Gravis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision
Phase II Paroxysmal Nocturnal Hemoglobinuria (PNH) trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.
Phase III Wilson Disease trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate the program
Phase III Thrombotic Microangiopathy trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Recruitment Challenges
Phase II Neuromyelitis Optica trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Pediatric clinical study is not feasible.
Phase I Healthy trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate program
Phase III Wilson Disease trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate the program
Phase I Healthy trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
The justification of the early termination of the trial: the study is early terminated due to the Coronavirus 2019 epidemic.
Phase I VTE Prophylaxis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
After completion of Part 1 and prior to initiating Part 2, the Sponsor decided to cease developing betrixaban, prompting early study closure.
Phase II C3 Glomerulonephritis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
The reason for terminating study early was inconclusive efficacy results. No safety findings were identified.
Phase II Hypophosphatasia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Withdrawn pending further review of clinical design.
Phase II Surgery trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Limited value as a single-arm study
Phase III Amyotrophic Lateral Sclerosis trial by Alexion Pharmaceuticals, Inc.. Stop reason: EFFICACY/FUTILITY.
The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.
Phase II HCV Infection trial by Alexion Pharmaceuticals, Inc.. Stop reason: SAFETY.
Nephrotoxicity
Phase III COVID-19 Severe Pneumonia trial by Alexion Pharmaceuticals, Inc.. Stop reason: EFFICACY/FUTILITY.
Met futility bar at interim analysis
Phase II Generalized Myasthenia Gravis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate program
Phase II Warm Autoimmune Hemolytic Anemia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Sponsor decision to terminate program
Phase II Chronic Hepatitis B trial by Alexion Pharmaceuticals, Inc.. Stop reason: SAFETY.
Safety concerns
Phase II Warm Autoimmune Hemolytic Anemia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Study is withdrawn due to the global impact of the COVID-19 pandemic.
Phase IV Hypophosphatasia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
R\&D portfolio review and in light of the global impact of the COVID-19 pandemic
Phase I Warm Autoimmune Hemolytic Anemia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Focus resources on a planned phase 2/3 study
Phase I Pemphigus trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Study objectives achieved
Phase II Lysosomal Acid Lipase Deficiency trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Myasthenia Gravis trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Neuromyelitis Optica trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I B-cell Chronic Lymphocytic Leukemia trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns.
Phase II Acute Graft-Versus-Host Disease trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Terminated early at the Sponsor's discretion, not due to safety concerns.
Phase I Advanced Solid Tumors trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
No stop-reason text available in the compact dataset.
Phase I Mucopolysaccharidosis III, Type B (MPS IIIB) trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
The Sponsor's decision to terminate the SBC-103 program was reached after review of the data from all interventional clinical studies of SBC-103.
Phase II Antibody Mediated Rejection trial by Alexion Pharmaceuticals, Inc.. Stop reason: OTHER/UNKNOWN.
Did not achieve statistical significance for primary endpoint
Phase II Antiphospholipid (aPL)-Positive trial by Alexion Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.
Screening discontinued early due to slow patient enrollment
Phase II HIV Infections trial by Alexion Pharmaceuticals, Inc.. Stop reason: SAFETY.
Safety concerns